Table 1.

Response rate and response duration according to the main pretreatment characteristics of the patients

VariablesDistribution (%)CR (%)Patients in response (% at 3 y)
Gender
    Female255339
    Male756853
Binet stage
    A218670
    B676136
    C125030
Rai stage
    03100100
    I-II7471*44
    III-IV234051
B-symptoms
    No677151
    Yes335043
Liver size
    Normal826546
    Enlarged186752
Spleen size
    Normal5576*49
    Enlarged455033
Lymphocyte count
    <50 × 109/L427549
    ≥50 × 109/L585952
LDT (n = 45)
    >6 mo607462
    ≤6 mo406138
Serum LDH (n = 65)
    Normal7774*66*
    Increased233325
β2-microglobulin (n = 60)
    <3 mg/L4979*51
    ≥3 mg/L515343
BM pattern (n = 62)
    Nondiffuse7174*49*
    Diffuse294438
Genetic abnormalities (n = 50)
    del(13q)345649
    +12226446
    del(11q)285040
    del(17p)110*
    Poor prognosis515454
CD38 expression (n = 49)
    <30%557459
    >30%456049
IgVH mutational status (n = 47)
    Mutated267590*
    Unmutated745740
ZAP-70 expression (n = 39)
    <20%4471*82*
    ≥20%565933
  • Abbreviations: LDT, lymphocyte doubling time; BM, bone marrow pattern.

  • * P < 0.05.

  • Cases with +12, del(11q), and/or del(17p).